{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:15:50Z","timestamp":1793164550638,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"am","delay-in-days":338,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.intimp.2023.110342","type":"journal-article","created":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T12:04:31Z","timestamp":1685793871000},"page":"110342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases"],"prefix":"10.1016","volume":"120","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7618-3585","authenticated-orcid":false,"given":"Xavier","family":"Boumaza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaux","family":"Lafaurie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6249-4534","authenticated-orcid":false,"given":"Emmanuel","family":"Treiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondine","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Pugnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0569-629X","authenticated-orcid":false,"given":"Damien","family":"Biotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"Jonathan","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Constantin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Puisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Moulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Alric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Renaudineau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Chauveau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Sailler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110342_b0005","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110342_b0010","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti\u2013tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.110342_b0015","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","article-title":"Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis","volume":"371","author":"Guillevin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110342_b0020","article-title":"Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis","volume":"12","author":"Stone","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2023.110342_b0025","first-page":"10","article-title":"Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis","author":"Jones","year":"2010","journal-title":"N Engl. J. Med"},{"key":"10.1016\/j.intimp.2023.110342_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: An update systematic review and meta -analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.intimp.2023.110342_b0035","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.intimp.2023.110342_b0040","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110342_b0045","doi-asserted-by":"crossref","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","article-title":"Association of aglobulinemia","volume":"1","author":"Barmettler","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.intimp.2023.110342_b0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2217\/imt-2017-0178","article-title":"Consequences of B-cell-depleting therapy: hypogammaglobulinemia and impaired B-cell reconstitution","volume":"10","author":"Sacco","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.110342_b0055","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.intimp.2023.110342_b0060","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1212\/NXI.0000000000000498","article-title":"Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders","volume":"5","author":"Marcinn\u00f2","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.intimp.2023.110342_b0065","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.seminhematol.2010.01.002","article-title":"Rituximab-Associated Infections","volume":"47","author":"Gea-Banacloche","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.intimp.2023.110342_b0070","unstructured":"D.M. Roberts, Rituximab-associated hypogammaglobulinemia: Incidence, predictors and outcomes in patients with multi-system autoimmune disease, 2014, 6."},{"key":"10.1016\/j.intimp.2023.110342_b0075","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1002\/acr.22993","article-title":"Pragmatic treatment of patients with systemic lupus erythematosus with rituximab: Long-term effects on serum immunoglobulins: Hypogammaglobulinemia after rituximab in SLE","volume":"69","author":"Reddy","year":"2017","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.intimp.2023.110342_b0080","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.intimp.2023.110342_b0085","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2018.02.010","article-title":"Predictors of hypogammaglobulinemia during rituximab maintenance therapy in rheumatoid arthritis: A 12-year longitudinal multi-center study","volume":"48","author":"Boleto","year":"2018","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.110342_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/8095695","article-title":"Risk factors and adverse events poorly predict infections and hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab","volume":"2016","author":"Besada","year":"2016","journal-title":"Autoimmune Dis."},{"key":"10.1016\/j.intimp.2023.110342_b0095","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2023.110342_b0100","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1093\/rheumatology\/ker417","article-title":"Total serum immunoglobulin levels in patients with RA after multiple B-cell depletion cycles based on rituximab: relationship with B-cell kinetics","volume":"51","author":"De La Torre","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2023.110342_b0105","article-title":"Rituximab-associated hypogammaglobulinaemia in ANCA-associated vasculitis and connective tissue diseases: a longitudinal observational study","volume":"7","author":"Padoan","year":"2020","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2023.110342_b0110","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1002\/art.40937","article-title":"predicting severe infection and effects of hypogammaglobulinemia during therapy with rituximab in rheumatic and musculoskeletal diseases","volume":"71","author":"Md Yusof","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2023.110342_b0115","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/rheumatology\/keu194","article-title":"Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis","volume":"53","author":"Besada","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2023.110342_b0120","doi-asserted-by":"crossref","unstructured":"van Vollenhoven RF, Fleischmann RM, Furst DE, et al. Longterm safety of rituximab: Final report of the rheumatoid arthritis global clinical trial program over 11 Years. J. Rheumatol. 6 (2015).","DOI":"10.3899\/jrheum.150051"},{"key":"10.1016\/j.intimp.2023.110342_b0125","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/ckj\/sfx014","article-title":"Immunoglobulin levels and infection risk with rituximab induction for anti-neutrophil cytoplasmic antibody-associated vasculitis","volume":"10","author":"Shah","year":"2017","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.intimp.2023.110342_b0130","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.intimp.2023.110342_b0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671503","article-title":"Rituximab associated hypogammaglobulinemia in autoimmune disease","volume":"12","author":"Tieu","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110342_b0140","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00296-021-04847-x","article-title":"Rituximab-associated hypogammaglobulinemia in autoimmune rheumatic diseases: a single-center retrospective cohort study","volume":"41","author":"Wade","year":"2021","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.intimp.2023.110342_b0145","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.intimp.2023.110342_b0150","first-page":"keac716","article-title":"Predictors of hypogammaglobulinemia in ANCA-associated vasculitis after a rituximab-based induction: a multicentre study","author":"Podest\u00e0","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2023.110342_b0155","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1136\/annrheumdis-2015-207841","article-title":"Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance","volume":"74","author":"Winthrop","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110342_b0160","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/cid\/ciaa127","article-title":"Serious infectious events and immunoglobulin replacement therapy in patients with autoimmune disease receiving rituximab: A retrospective cohort study","volume":"72","author":"Stabler","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.110342_b0165","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1471-2474-15-178","article-title":"The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease","volume":"15","author":"Marco","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.intimp.2023.110342_b0170","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-014-2509-2","article-title":"Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab","author":"Heusele","year":"2014","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2023.110342_b0175","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.2008.088302","article-title":"Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients","volume":"68","author":"Charlier","year":"2009","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.intimp.2023.110342_b0180","first-page":"S1","article-title":"Rituximab (MabThera) therapy and safety management. Clinical tool guide","volume":"75","author":"Pham","year":"2008","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.intimp.2023.110342_b0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2023.110342_b0190","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.autrev.2017.11.015","article-title":"Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and\/or malignant hematological disorders","volume":"17","author":"Tudesq","year":"2018","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2023.110342_b0195","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2010.03.025","article-title":"Does rituximab increase the incidence of infectious complications? A narrative review","volume":"15","author":"Kelesidis","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.intimp.2023.110342_b0200","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1002\/art.24998","article-title":"Depletion of functionally active CD20+ T cells by rituximab treatment","volume":"60","author":"Wilk","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2023.110342_b0205","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.imbio.2016.11.011","article-title":"Kinetic analysis of changes in T- and B-lymphocytes after anti-CD20 treatment in renal pathology","volume":"222","author":"Sent\u00eds","year":"2017","journal-title":"Immunobiology"},{"key":"10.1016\/j.intimp.2023.110342_b0210","unstructured":"Gl\u00fcck T, Kiefmann B, Grohmann M, et al. Immune status and risk for infection in patients receiving chronic immunosuppressive therapy, J. Rheumatol. 8."},{"key":"10.1016\/j.intimp.2023.110342_b0215","doi-asserted-by":"crossref","first-page":"e00035","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.intimp.2023.110342_b0220","doi-asserted-by":"crossref","DOI":"10.1136\/ard-2022-223401","article-title":"Risk factors for serious infections in ANCA-associated vasculitis","author":"Odler","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.intimp.2023.110342_b0225","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.autrev.2019.03.010","article-title":"Immunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature review","volume":"18","author":"Wijetilleka","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2023.110342_b0230","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/rheumatology\/key394","article-title":"Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases","volume":"58","author":"Wijetilleka","year":"2019","journal-title":"Rheumatology"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923006653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:10:05Z","timestamp":1761588605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923006653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":46,"alternative-id":["S1567576923006653"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110342","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110342","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110342"}}